Colossal Biosciences

Colossal Biosciences was founded in 2021 by entrepreneur Ben Lamm, its chief executive, and Harvard geneticist George Church, and is headquartered in Dallas, with labs in Boston and Melbourne. It edits the genomes of living species to recreate traits of extinct ones; its programs include the woolly mammoth, thylacine, dodo and bluebuck. In April 2025 it announced three gray wolf pups edited to carry dire wolf traits, a claim the IUCN SSC Canid Specialist Group disputed. Colossal acquired animal cloning company Viagen in November 2025. Its business model rests on spinning out technologies built for de-extinction, including computational biology platform Form Bio, plastic degradation startup Breaking and AI modeling company Astromech, which was valued at $2 billion in March 2026; TechCrunch, citing Axios, reported in July 2026 that Colossal had begun generating revenue. Its $200 million Series C, announced on Jan. 15, 2025 and led by TWG Global, valued it at $10.2 billion and brought total funding to $435 million. On Oct. 14, 2026 it launched GenoMorph, an AI platform that identified about 2,300 DNA editing targets for the dodo.